Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697591 · ClinicalTrials.gov registry record · Phase 1
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT02697591 is a Phase 1 study that has completed, run by Incyte Biosciences International Sàrl. The registered enrollment target is 100 participants.
The verdict
NCT02697591, a Phase 1 study, has completed, sponsored by Incyte Biosciences International Sàrl.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.
Interventions
- DRUG INCAGN01876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-06-20 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697591
The ClinicalTrials.gov registry entry for NCT02697591 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Biosciences International Sàrl, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCAGN01876 is the first listed.
NCT02697591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697591 about?
NCT02697591 is a clinical study titled "A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors". This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose ...
What is the current status of trial NCT02697591?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2016-06-20. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT02697591?
The interventions under investigation include: INCAGN01876 (DRUG).
Who is sponsoring clinical trial NCT02697591?
This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.